Managing the Risks of Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Current and Emerging Therapies
Robert Dreicer, MD, MS, MACP, FASCO
Head, Medical Oncology Section
Deputy Director, University of Virginia Cancer Center
Associate Director for Clinical Research
Co-Director, Paul Mellon Urologic Oncology Center
Professor of Medicine and Urology
University of Virginia School of Medicine
Thomas Cartwright, MD
Co-Chairman, US Oncology GI Research
This enduring activity will cover the treatment and management of patients with metastatic hormone-sensitive prostate cancer.
This CME initiative is designed to meet the educational needs of urologists, medical oncologists, primary care providers, cardiologists, and other healthcare providers involved in the treatment and management of patients with prostate cancer.
On completing the program, attendees should be able to:
- Discuss the metabolic and cardiovascular changes observed with androgen deprivation therapy
- Describe recommended management strategies to minimize cardiovascular risks in patients with prostate cancer
- Evaluate the efficacy and safety of current and emerging treatment options for metastatic hormone-sensitive prostate cancer
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the treatment and management of patients with Metastatic Hormone-Sensitive Prostate Cancer.
Credits: 1.0 ANCC Contact Hour.
CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Robert Dreicer, MD (Program Chair) reports that he has served as a consultant for Bristol Myer-Squibb, Incyte, Genentech/Roche, Pfizer, and Astra Zeneca.
Thomas Cartwright, MD reports that he has served on speaker’s bureau for Taiho, Amgen, and Heron. He also serves as a consultant for Taiho.
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development for Med Learning Group, has nothing to disclose.
Sharine Griggs, Program Manager for Med Learning Group, has nothing to disclose.
Brooke Hefele, Accreditation and Outcomes Coordinator, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and nonapproved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the live activity.
3. Submit the evaluation form to Med Learning Group.
You will receive your certificate as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at; email@example.com
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: October 11, 2019
EXPIRATION DATE: October 11, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.